Ronald G. Stoller - Concepedia

Author

Ronald G. Stoller

UPMC Hillman Cancer Center

Also Known As

Friedland, David M., R G Stoller, R Stoller, R. G. Stoller, R. Stoller, R.G. Stoller, Ronald G. Stoller, Ronald Stoller

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

UPMC Hillman Cancer Center University of Pittsburgh National Cancer Institute Penn State Milton S. Hershey Medical Center University of Pittsburgh Medical Center

About

Ronald G. Stoller is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	27	1.4K
2	Health Sciences	5	5	176
3	Biochemistry	2	2	55
4	Engineering	1	1	32
5	Biomedical Engineering	1	1	32

Ronald G. Stoller

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer Jeffrey Crawford, Howard Ozer, Ronald G. Stoller, New England Journal of Medicine	1991	1.4K
Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity Ronald G. Stoller, Kenneth R. Hande, Samuel A. Jacobs, New England Journal of Medicine Drug SafetyStandard DeviationsPharmacokinetic ModelingMedicineHematology	1977	395
7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. Samuel A. Jacobs, Ronald G. Stoller, Bruce A. Chabner, Journal of Clinical Investigation Medicinal ChemistryPharmacological StudyHigh Dose MethotrexateRhesus MonkeysMedicine	1976	256
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors Jordi Rodón, Hussein Tawbi, Anne Thomas, Clinical Cancer Research	2014	228
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies Suresh S. Ramalingam, Robert A. Parise, Ramesh K. Ramananthan, Clinical Cancer Research	2007	196
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer Brian A. Boone, Jennifer Steve, Alyssa M. Krasinskas, Journal of Surgical Oncology	2013	190
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller, Journal of Clinical Oncology	2015	176
Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers Ramesh K. Ramanathan, Merrill J. Egorin, Julie L. Eiseman, Clinical Cancer Research	2007	87
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy John A. Glaspy, Giselle C Bleecker, Jeffrey Crawford, European Journal of Cancer MedicineCancer ManagementCombined Modality TreatmentCancer TreatmentRadiation Oncology	1993	81
Venom Immunotherapy in Hymenoptera Sting Allergy U Thurnheer, Ulrich Müller, Ronald G. Stoller, Allergy	1983	70

Page 1